评估 pegenzileukin(SAR444245/THOR-707)联合 pembrolizumab 或 cetuximab 治疗晚期转移性胃肠道癌:PEGATHOR 2 期研究
Evaluating pegenzileukin (SAR444245/THOR-707) in combination with pembrolizumab or cetuximab in advanced metastatic gastrointestinal cancer: the PEGAT
ALL SOURCES
Evaluating pegenzileukin (SAR444245/THOR-707) in combination with pembrolizumab or cetuximab in advanced metastatic gastrointestinal cancer: the PEGAT
Pan-cancer analysis shows that BCAP31 is a potential prognostic and immunotherapeutic biomarker for multiple cancer types.
BCAP31 有潜力作为癌症免疫学的生物标志物,特别是与免疫细胞浸润相关,并可作为不良预后的指标。这些发现提供了一个新的视角,可为开发更具针对性的癌症治疗策略提供信息。
The tight junction protein claudin 6 is a potential target for patient-individualized treatment in esophageal and gastric adenocarcinoma and is associ
CLDN6 mRNA 高表达与调控细胞生长、增殖和细胞-基质相互作用的多种不同生物学通路失调相关。
Fetal gut cell-like differentiation in esophageal adenocarcinoma defines a rare tumor subtype with therapeutically relevant claudin-6 positivity and S
Multifaceted role of interleukin-32 in inflammatory diseases and cancer.
a Single-arm, Single-center, Open Clinical Study
这是一项观察性研究,观察 T 细胞治疗胃癌、食管癌、宫颈癌的真实世界诊疗与结局。登记适应症还包括非小细胞肺癌、乳腺癌(登记共 5 项)。当前状态:招募中。计划入组 10 例。试验地点:中国 · 郑州(共 1 个中心,其中中国 1 个)。登记号:NCT06431100。
Characteristics of auto-quantified tumor-infiltrating lymphocytes and the prognostic value in adenocarcinoma of the esophagogastric junction, gastric
我们发现,通过图像处理算法评估,TIL 在 ESCC、GAC 和 AEGJ 中存在差异。此外,这三种癌症中的 TIL 是一个独立的预后因素。这增强了我们对这三种肿瘤独特免疫特征的理解,从而改善患者预后。
Novel insight into the role of immunotherapy in gastrointestinal cancer (Review).
共 8 条
MEMBER ACCOUNT
登录成功会直接打开下一页。